Schizophrenia Clinical Trials in Phoenix

Showing 121-136 of 136 trials

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187

Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.

SchizophreniaPsychotic DisordersBipolar Disorder

Eli Lilly and Company130 participantsStarted Apr 2001

El Centro, California, United States • Jacksonville, Florida, United States • Miami, Florida, United States +13 more locations

COMPLETEDPhase 3256 miles

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

NCT00051298

This study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial.

Schizophrenia

Eli Lilly and Company107 participantsStarted Nov 2002

Little Rock, Arkansas, United States • Cerritos, California, United States • San Diego, California, United States +22 more locations

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

Schizophrenia Trials in Other Cities

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

Other Conditions in Phoenix